ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 1732 • ACR Convergence 2021

    Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Ruoning Ni1, Jiayi Zheng2 and Ruru Guo3, 1Saint Agnes Healthcare, Baltimore, MD, 2Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), 3Renji Hospital, Shanghai, China (People's Republic)

    Background/Purpose: The efficacy of B cell activator factor/B lymphocyte stimulator inhibitors (BAFFi/BLySi) for systemic lupus erythematosus (SLE) has been proven in clinical trials. However, it…
  • Abstract Number: 0429 • ACR Convergence 2021

    Causes and Characteristics of Death in ANCA-Associated Vasculitis – A Large, Real-Life, Contemporary Cohort Analysis

    Guy Katz1, Claire Cook2, Xiaoqing Fu1, Hyon K. Choi3 and Zachary S. Wallace4, 1Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, 3Massachusetts General Hospital, Lexington, MA, 4Harvard Medical School, Boston, MA

    Background/Purpose: Despite improvements, patients with ANCA-associated vasculitis (AAV) have a higher risk of death than the general population. Contemporary treatment is associated with high remission…
  • Abstract Number: 1288 • ACR Convergence 2021

    First Year Infection Risk in SLE Patients Treated with Rituximab versus Standard of Care Treatment: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)

    Mia Rodziewicz1, Sarah Dyball1, Stephen McDonald1, Emily Sutton1, Ben Parker1, The British Isles Lupus Assessment Group2 and Ian N. Bruce1, 1University of Manchester, Manchester, United Kingdom, 2Lupus Trust, London

    Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have an increased risk of infection compared to the general population. We aimed to assess the early risk…
  • Abstract Number: 1758 • ACR Convergence 2021

    WITHDRAWN

  • Abstract Number: L04 • ACR Convergence 2020

    Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program

    Kevin L Winthrop1, Arne Yndestad2, Dan Henrohn3, Hyejin Jo4, Sara Marsal5, Maria Galindo6, Annette Diehl7, Andrea B Shapiro8 and Stanley B Cohen9, 1Oregon Health & Science University, Portland, OR, 2Pfizer Inc, Oslo, Norway, 3Pfizer Inc, Sollentuna, Sweden, 4Syneos Health, Raleigh, NC, 5Vall d’Hebron Hospital, Barcelona, Spain, 6Rheumatology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain, 7Pfizer Inc, Collegeville, PA, 8Pfizer Inc, Peapack, NJ, 9Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: Patients (pts) with RA have increased susceptibility to seasonal influenza and its complications.1 The COVID-19 pandemic highlights the need to understand acute respiratory RNA…
  • Abstract Number: 0002 • ACR Convergence 2020

    Hydroxychloroquine and Chloroquine and Hospitalizations for Viral Infection in the Pre-COVID-19 Era

    Cristiano Moura1, Marina Machado1, Celline Almeida-Brasil1, Jeffrey R Curtis2, Kevin Winthrop3, Michal Abrahamowicz1 and Sasha Bernatsky4, 1McGill University, Montreal, Canada, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Oregon Health & Science University, Portland, OR, 4The Research Institute of the McGill University Health Centre, Montreal, ON, Canada

    Background/Purpose: Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to have antiviral properties and were considered as potential therapeutic options amid the COVID-19 pandemic. The…
  • Abstract Number: 0456 • ACR Convergence 2020

    Reduced Risk of Serious Pneumococcal Infection up to 10 Years After Immunization with 7-valent Conjugated Pneumococcal Vaccine in Patients with Inflammatory Arthritis

    Johanna Nagel1, Göran Jönsson2, Jan Åke Nilsson3, Chanchai Manuswin4, Martin Englund5, Tore Saxne1, Pierre Geborek1 and Meliha Kapetanovic1, 1Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, 2Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, 4Centre of Registers South, Skåne University Hospital, Lund, Sweden, Lund, Sweden, 5Lund University, Lund, Sweden

    Background/Purpose: The aim was to examine the rates of putative pneumococcal infections up to 10 years before and after administration of heptavalent conjugated pneumococcal vaccine…
  • Abstract Number: 0776 • ACR Convergence 2020

    The Influence of Adipokine Profile and Periodontal Infection in Early Stages of Rheumatoid Arthritis and First-degree Relatives

    Consuelo Romero-Sanchez1, Juliette De Avila2, Jeimmy Andrea Chaparro-Sanabria3, Philipe Chalem Choueka4, Juan Manuel Bello-Gualtero5, Alejandro Ramos-Casallas2, Lorena Chila-M2 and Wilson Bautista-Molano6, 1Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, 2Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, 3Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, 4Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, 5Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, 6University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia

    Background/Purpose: Early RA (eRA) patients have a significant incidence of periodontal inflammation and overweight/obesity. A similar degree of disease activity, functional disability and health-related quality…
  • Abstract Number: 1694 • ACR Convergence 2020

    Risk Factors Associated with Pneumocystis Jirovecii Pneumonia in Juvenile Myositis in North America

    Sara Sabbagh1, Jessica Neely2, Albert Chow3, Marietta DeGuzman4, Jamie Lai5, Svetlana Lvovich6, Tara McGrath7, Maria Pereira8, Iago Pinal-Fernandez9, Jordan Roberts10, Kelly Rouster-Stevens11, Heinrike Schmeling12, Anjali Sura13, Gabriel Tarshish14, Lori Tucker15, Lisa G. Rider16 and Susan Kim17, 1Medical College of Wisconsin, Fox Point, WI, 2UCSF, San Francisco, CA, 3Loma Linda University, San Bernardino, CA, 4Baylor College of Medicine, Houston, 5University of Colorado, The Woodlands, TX, 6St Christopher's Hospital for Children, Philadelphia, PA, 7University of British Columbia, Vancouver, BC, Canada, 8Baylor College of Medicine, Houston, TX, 9National Institutes of Health, Bethesda, MD, 10Boston Children's Hospital, Boston, MA, 11Emory University/Children's Healthcare of Atlanta, Atlanta, GA, 12University of Calgary, Calgary, AB, Canada, 13Upstate University Hospital, Syracuse, NY, 14Children's Hospital at Montefiore, New York, NY, 15BC Children's Hospital, Vancouver, BC, Canada, 16Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, 17UCSF Benioff Children's Hospital, San Francisco, CA

    Background/Purpose: Pneumocystis jirovecii pneumonia (PJP) is associated with significant morbidity and mortality in adult myositis patients; however, few studies have examined PJP in juvenile myositis…
  • Abstract Number: 0005 • ACR Convergence 2020

    Geographical Variations in COVID-19 Perceptions and Patient Management: A National Survey of Rheumatologists

    Bella Mehta1, Deanna Jannat-Khah2, Carol Mancuso3, Anne Bass1, Carine Moezinia4, Allan Gibofsky3, Susan Goodman5 and Said Ibrahim6, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Hospital for Special Surgery, New York City, NY, 3Hospital for Special Surgery, New York City, 4Hospital for Special Surgery, New York, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 6Weill Cornell Medicine, Cleveland, OH

    Background/Purpose: To investigate the perceptions and behaviors of rheumatologists in the United States (US) regarding the risk of COVID-19 for their autoimmune patients and the…
  • Abstract Number: 0520 • ACR Convergence 2020

    Antiphospholipid Antibodies and Thrombotic Events in COVID-19 Patients Hospitalized in Medicine Ward

    Alexandre Le Joncour1, Corinne Frere1, Isabelle Martin-Toutain1, Paul Gougis1, Pascale Ghillani-Dalbin1, Georgina Maalouf1, Matheus Vieira1, Anne-Genevieve Marcelin1, Joe-Elie Salem1, Yves Allenbach2, David Saadoun3, Olivier Benveniste4 and Patrice Cacoub1, 1APHP, paris, France, 2Sorbonne Université, Paris, Ile-de-France, France, 3AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, PAris, France, 4Sorbonne Université, paris, France

    Background/Purpose: A high prevalence of thrombotic events has been reported in critically ill COVID-19 patients but data on the prevalence of thrombosis in ward patients…
  • Abstract Number: 0914 • ACR Convergence 2020

    Serious Infections in People with Systemic Sclerosis: A National U.S. Study

    Jasvinder Singh1 and John Cleveland1, 1University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: To study incidence, time-trends and outcomes of serious infections in systemic sclerosis (SSc).Methods: We used the 1998-2016 U.S. National Inpatient Sample data. We examined…
  • Abstract Number: 1758 • ACR Convergence 2020

    Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data

    Robin Dore1, Jenya Antonova2, Lawrence Chang2, Suying Li3, Haifeng Guo3, Yuanyuan Ji3 and Mark Genovese4, 1Private practice, Tustin, CA, 2Gilead Sciences, Foster City, CA, 3Chronic Disease Research Group, Minneapolis, MN, 4Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: RA patients have an increased risk of infection1 and venous thromboembolism (VTE)2. Although rates of serious infection and VTE have been reported for Medicare…
  • Abstract Number: 0014 • ACR Convergence 2020

    Does the Type of Rheumatic Disease or Biologic Treatment Increase the Risk of Developing Severe COVID-19?

    Fernando López-Gutierrez1, Antía García-Fernández1, Jesús Loarce-Martos1, Laura Calvo-Sanz1, Ivan Del Bosque-Granero2, Veronica Garcia2, Boris Blanco-Cáceres1, Cristina Pijoan-Moratalla1, Lourdes Villalobos-Sánchez3, Javier Bachiller-Corral1 and Mónica Vázquez1, 1Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 3Rheumatology, Hospital Universitario Ramón y Cajal, Madrid

    Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) have an increased risk for infection related to immunosuppression secondary to their disease, treatment and comorbidities. Nonetheless recent…
  • Abstract Number: 0545 • ACR Convergence 2020

    The Use of Tocilizumab and Tofacitinib in Patients with Resolved Hepatitis B Infection: A Case Series

    Naomi Serling-Boyd1, Amir Mohareb2, Arthur Kim2, Emily Hyle2 and Zachary Wallace3, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Newton, MA

    Background/Purpose: The use of immunosuppressive medications in patients with a history of hepatitis B virus (HBV) infection is associated with an increased risk of HBV…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology